Mayo Clinic Cancer Center, Phoenix, AZ, USA.
Mayo Clinic Cancer Center, 200 1st St SW, Rochester, MN, 55905, USA.
Curr Treat Options Oncol. 2019 Aug 19;20(9):74. doi: 10.1007/s11864-019-0670-1.
In 2017, the World Health Organization (WHO) classification for pancreatic NET was updated to include a new category of well-differentiated high-grade (Ki 67 > 20%) pancreatic tumors (NET G3), distinct from high-grade poorly differentiated neuroendocrine carcinoma (NEC). NET G3 are considered a molecularly, radiologically, and prognostically distinct entity compared to NEC and NET G1/G2. The optimal first-line management in NET G3 and sequencing therapies remains a challenge awaiting future trials taking into consideration the unique characteristics of this category. In this review, we aim to summarize the current evidence in the management of NET G3.
2017 年，世界卫生组织（WHO）对胰腺神经内分泌肿瘤的分类进行了更新，纳入了一种新的分化良好的高级别（Ki-67>20%）胰腺肿瘤（NET G3）类别，与高级别低分化神经内分泌癌（NEC）不同。与 NEC 和 NET G1/G2 相比，NET G3 被认为在分子、影像学和预后方面具有独特性。NET G3 的一线治疗方法以及治疗顺序仍然是一个挑战，有待未来的临床试验来考虑这一类别独特的特征。在这篇综述中，我们旨在总结 NET G3 管理方面的现有证据。
